COMPASS Pathways plc
CMPSHealthcareNASDAQMedical Care Facilities · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCOMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. Valued at $1.55B, CMPS is a small-cap name in its sector. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Market Cap
$1.55B
Beta
2.56
P/E (TTM)
—
P/E (Fwd)
-7.80
EPS (TTM)
$-3.61
EPS (Fwd)
$-1.43
ROE
-319.1%
ROA
-29.1%
Cash
$433.3M
Total Debt
$54.6M
Free CF
$249.9M
52W Change
78.0%
Annual Financials
Cash vs Debt
Where CMPS stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CMPS finished 4.36% below its 150-day moving average ($11.24) and 5.60% above its 200-day moving average ($10.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMPS overbought or oversold?
At the October 19, 2026 close, CMPS's RSI(14) was 23.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $433.3M in cash comfortably exceeding the $54.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $249.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -319.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
COMPASS Pathways plc's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CMPS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence COMPASS Pathways plc's trajectory.